CClinicalTrials.gg
Sign In
RecruitingNCT07753226Updated Sep 10, 2026

A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

A Phase 1 interventional study of SI-B036 in Breast Cancer and Solid Tumor, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic breast cancer and other solid tumors.

Read the detailed description

The study consists of two phases: a dose-escalation phase (Phase Ia) and an expansion phase (Phase Ib).

02

Conditions studied

  • Breast Cancer
  • Solid Tumor

Browse trials for

03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Voluntarily sign the informed consent form and comply with the protocol requirements;
  2. No gender restriction;
  3. Age: ≥18 years and ≤75 years;
  4. Expected survival time ≥3 months;
  5. Locally advanced or metastatic breast cancer and other solid tumors;
  6. Agree to provide archived tumor tissue specimens from the primary or metastatic site within 2 years, or fresh tissue samples;
  7. Must have at least one measurable lesion as defined by RECIST v1.1;
  8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
  9. Toxicity from prior antitumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
  10. No severe cardiac dysfunction, with left ventricular ejection fraction ≥50%;
  11. Organ function levels must meet the required criteria;
  12. Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time ≤1.5 × upper limit of normal;
  13. Urine protein ≤1+ or ≤1000 mg/24 h;
  14. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with a negative serum pregnancy result, and they must be non-lactating; all enrolled patients (both males and females) must adopt adequate barrier contraceptive measures throughout the entire treatment period and for 6 months after treatment completion;
  15. The trial participant must be able and willing to comply with the protocol-specified visits, treatment plan, laboratory tests, and other study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Use of chemotherapy, biotherapy, immunotherapy, or similar treatments within 4 weeks or 5 half-lives prior to the first dose;
  2. Receipt of immunosuppressive drug therapy within 2 weeks prior to the first dose;
  3. History of severe cardiac or cerebrovascular disease;
  4. Prolonged QTc interval, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias;
  5. Active autoimmune diseases and inflammatory diseases;
  6. Prior experience of ≥ Grade 3 toxicity related to anti-angiogenic therapy during previous anti-angiogenic treatment;
  7. Diagnosis of another solid tumor within 5 years prior to the first dose;
  8. Unstable thrombotic events requiring therapeutic intervention within 6 months prior to the first dose;
  9. Poorly controlled hypertension;
  10. Diabetes mellitus with poor glycemic control;
  11. History of interstitial lung disease (ILD) requiring steroid therapy, or current ILD, or ≥ Grade 2 radiation pneumonitis;
  12. Concurrent pulmonary disease resulting in severe impairment of respiratory function;
  13. Active central nervous system metastases;
  14. History of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of SI-B036;
  15. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
  16. Positive for human immunodeficiency virus antibodies, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  17. Active infection requiring systemic therapy within 4 weeks prior to the first dose of the study drug;
  18. Presence of pleural, abdominal, or pelvic effusion, or pericardial effusion requiring drainage and/or accompanied by symptoms within 4 weeks prior to the first dose of the study drug;
  19. Imaging findings suggesting tumor invasion or encasement of major thoracic blood vessels, pericardium, or heart;
  20. Trial participants with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to screening;
  21. History of fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the first dose;
  22. Use of another investigational drug within 4 weeks or 5 half-lives prior to the first dose;
  23. Pregnant or breastfeeding women;
  24. Other conditions deemed by the investigator to make the participant unsuitable for participation in this clinical trial.
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    SI-B036

    Participants receive SI-B036 for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: SI-B036

Interventions

  • DrugSI-B036

    Administration by intravenous infusion for a cycle of 3 weeks.

05

What researchers measure

Primary outcomes

  1. Phase Ia: Dose limiting toxicity (DLT)

    DLTs are assessed according to NCI-CTCAE v5.0 during the first cycle and defined as occurrence of any of the toxicities in DLT definition if judged by the investigator to be possibly, probably or definitely related to study drug administration.

    Time frame: Up to 21 days after the first dose

  2. Phase Ia: Maximum tolerated dose (MTD)

    MTD is defined as the highest dose level at which no more than 1 in 6 participants experienced a DLT during the first cycle.

    Time frame: Up to 21 days after the first dose

  3. Phase Ib: Recommended Phase II Dose (RP2D)

    The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of SI-B036.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Treatment-Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of SI-B036. The type, frequency and severity of TEAE will be evaluated during the treatment of SI-B036.

    Time frame: Up to approximately 24 months

  2. Cmax

    Cmax is defined as the maximum observed drug concentration in plasma after administration.

    Time frame: Up to approximately 24 months

  3. Tmax

    Tmax is defined as the time required to reach the maximum drug concentration in plasma following drug administration.

    Time frame: Up to approximately 24 months

  4. T1/2

    T1/2 is defined as the time required for the plasma concentration of a drug to decrease by 50% during the elimination phase.

    Time frame: Up to approximately 24 months

  5. AUC0-t

    AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration.

    Time frame: Up to approximately 24 months

  6. CL (Clearance)

    Clearance (CL) is the volume of plasma from which a drug is completely removed per unit time.

    Time frame: Up to approximately 24 months

  7. Ctrough

    Ctrough is defined as the lowest serum concentration prior to the next dose will be administered.

    Time frame: Up to approximately 24 months

  8. Anti-drug Antibody (ADA)

    Frequency of anti-SI-B036 antibody (ADA) will be investigated.

    Time frame: Up to approximately 24 months

  9. Progression-free Survival (PFS)

    Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.

    Time frame: Up to approximately 24 months

  10. Objective Response Rate (ORR)

    Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).

    Time frame: Up to approximately 24 months

  11. Disease Control Rate (DCR)

    Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria.

    Time frame: Up to approximately 24 months

  12. Duration of Response (DOR)

    Duration of Response (DOR) is defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.

    Time frame: Up to approximately 24 months

06

Study locations

1 of 1 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
    • Binghe Xu · Contact
    Recruiting
07

Registry details

Key details

Study ID
NCT07753226
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Aug 7, 2026
Start date
Aug 18, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
+8615013238943

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Breast Neoplasms→

Other studies from this sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Start the discussion